Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Click here to view

Presentation

Strategic Formulation Development for AAV Delivered Gene Therapies – a Case Study

Download PDF